NOBLE: A Phase 2 multi-center randomized double-blind placebo-controlled study to evaluate the efficacy and safety of T-817 in patients with mild to moderate Alzheimer's disease
ID Number 91-0208-00020Principal Investigator(s)
Department(s) or Division(s)
Volunteers are being recruited for the NOBLE study. This study is evaluating an investigational drug for patients with mild to moderate Alzheimer's disease that may work by protecting brain cells which would result in improved memory. Participants will receive the study drug or a placebo and participate in the study for about 14 months which includes screening about one year study treatment and follow up to check safety. We will also be studying the effect of the drug on brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF). The study needs women and men aged 55-85 years old with mild to moderate Alzheimer's disease who have been receiving donepezil (Aricept®) treatment for at least 6 months and who have a study partner with regular contact that can attend study visits. Participation will be at no cost to the participant. For more information about the NOBLE study please contact one of our coordinators at 212-241-8329. This research will take place at Mount Sinai's Upper East Side campus.
Recruiting Patients: Yes